{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:29:37Z","timestamp":1772641777898,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"13-14","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:p>While glucocorticoids remain the standard first-line treatment for chronic idiopathic eosinophilic pneumonia (CIEP), the long-term use is marred by significant side effects. This case study explores the effectiveness of mepolizumab, an anti-interleukin\u20115 (IL-5) monoclonal antibody, as a\u00a0novel corticosteroid-free alternative in treating CIEP. A\u00a050-year-old woman presented with a\u00a03-week history of progressive shortness of breath, dry cough and night sweats. The blood tests showed eosinophilia, and chest radiography identified lung consolidations. The CIEP was confirmed, ruling out other conditions through a\u00a0detailed clinical and bronchoscopic work-up. The patient declined to be treated with systemic glucocorticoids. Treatment with mepolizumab was remarkable for effectively resolving symptoms and improving radiological findings without any prior or concurrent glucocorticoid therapy. Notably, the patient remained relapse-free over a\u00a02-year follow-up, underscoring mepolizumab\u2019s efficacy as a\u00a0corticosteroid-free treatment for CIEP. This case study calls for further research into anti-IL\u20115 treatment of rare respiratory conditions.<\/jats:p>","DOI":"10.1007\/s00508-024-02406-5","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T11:02:23Z","timestamp":1723114943000},"page":"453-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Healing chronic idiopathic eosinophilic pneumonia using mepolizumab alone without corticosteroids"],"prefix":"10.1007","volume":"137","author":[{"given":"Katharina","family":"Moritz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Amelunxen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Vafai-Tabrizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg-Christian","family":"Funk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"2406_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/TCRM.S157882","volume":"15","author":"M Crowe","year":"2019","unstructured":"Crowe\u00a0M, Robinson\u00a0D, Sagar\u00a0M, Chen\u00a0L, Ghamande\u00a0S. Chronic eosinophilic pneumonia: clinical perspectives. Ther Clin Risk Manag. 2019;15:397\u2013403.","journal-title":"Ther Clin Risk Manag"},{"key":"2406_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1750-1172-1-11","volume":"1","author":"E Marchand","year":"2006","unstructured":"Marchand\u00a0E, Cordier\u00a0JF. Idiopathic chronic eosinophilic pneumonia. Orphanet J Rare Dis. 2006;1:11.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2406_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1183\/09031936.03.00085603","volume":"22","author":"E Marchand","year":"2003","unstructured":"Marchand\u00a0E, Etienne-Mastroianni\u00a0B, Chanez\u00a0P, Lauque\u00a0D, Leclerc\u00a0P, Cordier\u00a0JF, et\u00a0al. Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other? Eur Respir\u00a0J. 2003;22(1):8\u201313.","journal-title":"Eur Respir J"},{"issue":"6","key":"2406_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00408-017-0048-8","volume":"195","author":"S Katoh","year":"2017","unstructured":"Katoh\u00a0S, Ikeda\u00a0M, Matsumoto\u00a0N, Shimizu\u00a0H, Abe\u00a0M, Ohue\u00a0Y, et\u00a0al. Possible role of IL-25 in eosinophilic lung inflammation in patients with chronic eosinophilic pneumonia. Lung. 2017;195(6):707\u201312.","journal-title":"Lung"},{"issue":"4","key":"2406_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.alit.2019.05.006","volume":"68","author":"Y Suzuki","year":"2019","unstructured":"Suzuki\u00a0Y, Suda\u00a0T. Eosinophilic pneumonia: a\u00a0review of the previous literature, causes, diagnosis, and management. Allergol Int. 2019;68(4):413\u20139.","journal-title":"Allergol Int"},{"issue":"4","key":"2406_CR6","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jaip.2022.12.022","volume":"11","author":"Q Delcros","year":"2023","unstructured":"Delcros\u00a0Q, Taill\u00e9\u00a0C, Vall\u00e9e\u00a0A, Brun\u00a0AL, Chenivesse\u00a0C, Couture\u00a0P, et\u00a0al. Targeting IL-5\/5R for the treatment of idiopathic chronic eosinophilic pneumonia. J\u00a0Allergy Clin Immunol Pract. 2023;11(4):1317\u20131319.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2406_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00408-020-00336-3","volume":"198","author":"E Brenard","year":"2020","unstructured":"Brenard\u00a0E, Pilette\u00a0C, Dahlqvist\u00a0C, Colinet\u00a0B, Schleich\u00a0F, Roufosse\u00a0F, et\u00a0al. Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia. Lung. 2020;198(2):355\u201360.","journal-title":"Lung"},{"key":"2406_CR8","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-5-3","author":"A Kisling","year":"2020","unstructured":"Kisling\u00a0A, Jones\u00a0J, Hixson\u00a0C, Hostler\u00a0D, Hostler\u00a0J. Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance. Drugs Context. 2020; https:\/\/doi.org\/10.7573\/dic.2020-5-3.","journal-title":"Drugs Context"},{"issue":"5","key":"2406_CR9","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.jaip.2018.03.011","volume":"6","author":"J Allen","year":"2018","unstructured":"Allen\u00a0J, Wert\u00a0M. Eosinophilic pneumonias. J\u00a0Allergy Clin Immunol Pract. 2018;6(5):1455\u201361.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2406_CR10","first-page":"e14047","volume":"13","author":"N Teixeira","year":"2021","unstructured":"Teixeira\u00a0N, Santos\u00a0MI, Pedro\u00a0F, Pinto\u00a0MJ, Mestre\u00a0A. Idiopathic chronic eosinophilic pneumonia. Cureus. 2021;13(3):e14047.","journal-title":"Cureus"},{"issue":"11","key":"2406_CR11","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.21037\/jtd-22-511","volume":"14","author":"N Takeuchi","year":"2022","unstructured":"Takeuchi\u00a0N, Arai\u00a0T, Sasaki\u00a0Y, Akira\u00a0M, Matsuda\u00a0Y, Tachibana\u00a0K, et\u00a0al. Predictive factors for relapse in corticosteroid-treated patients with chronic eosinophilic pneumonia. J\u00a0Thorac Dis. 2022;14(11):4352\u201360.","journal-title":"J Thorac Dis"},{"issue":"15","key":"2406_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/JAA.S343272","volume":"9","author":"H Tashiro","year":"2022","unstructured":"Tashiro\u00a0H, Takahashi\u00a0K, Kurihara\u00a0Y, Sadamatsu\u00a0H, Kuwahara\u00a0Y, Kimura\u00a0S, et\u00a0al. Anti-IL\u20115 agents for the treatment of idiopathic chronic eosinophilic pneumonia: a\u00a0case series. J\u00a0Asthma Allergy. 2022;9(15):169\u201377.","journal-title":"J Asthma Allergy"},{"issue":"11","key":"2406_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/02770903.2018.1534966","volume":"56","author":"RY Lin","year":"2019","unstructured":"Lin\u00a0RY, Santiago\u00a0TP, Patel\u00a0NM. Favorable response to asthma-dosed subcutaneous mepolizumab in eosinophilic pneumonia. J\u00a0Asthma. 2019;56(11):1193\u20137.","journal-title":"J Asthma"},{"issue":"10","key":"2406_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1056\/NEJMoa0805435","volume":"360","author":"P Nair","year":"2009","unstructured":"Nair\u00a0P, Pizzichini\u00a0MMM, Kjarsgaard\u00a0M, Inman\u00a0MD, Efthimiadis\u00a0A, Pizzichini\u00a0E, et\u00a0al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N\u00a0Engl J Med. 2009;360(10):985\u201393.","journal-title":"N Engl J Med"},{"issue":"4","key":"2406_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/17476348.2020.1718495","volume":"14","author":"G Hillas","year":"2020","unstructured":"Hillas\u00a0G, Fouka\u00a0E, Papaioannou\u00a0AI. Antibodies targeting the interleukin\u20115 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a\u00a0review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Rev Respir Med. 2020;14(4):353\u201365.","journal-title":"Expert Rev Respir Med"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02406-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02406-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02406-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:33:38Z","timestamp":1752136418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02406-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":15,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2406"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02406-5","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.\u00a0Moritz, C.\u00a0Amelunxen, M.\u00a0Bergmann, F.\u00a0Vafai-Tabrizi and G.-C.\u00a0Funk declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case. Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}